ResultsIQ

ResultsIQ › Latest results › Fineotex Chemical Limited

Fineotex Chemical Limited Q4 FY25 results press release summary

NSE: FCL · BSE: 533333

Results press release of 20 May 2025, summarised by AI from the filing.

Fineotex Chemical FY25 total income ₹557.64 cr, down 4.76%; greenfield expansion to add 15,000 MTPA capacity by Q2 FY26.

Key takeaways

  1. Capacity guidance Greenfield expansion to add 15,000 MTPA, raising total installed capacity to 1,20,000 MTPA, expected to commence operations in Q2 FY26.
  2. New verticals Water Treatment and Oil & Gas delivered strong performance with substantial increase in volumes and value contribution.
  3. Customer additions Added 30 new customers during fourth quarter and developed 15 new products.
  4. FMCG softness FMCG, Cleaning & Hygiene segment witnessed a temporary softness in volumes, though underlying demand fundamentals remain intact.

Original filing on BSE

Fineotex Chemical Limited Q1 FY27 results

As filed: Revenue ₹377 cr (+175% year on year), EBITDA ₹59.1 cr (+137% year on year), PAT ₹48.2 cr (+93% year on year), EBITDA margin 15.7% (−255 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹314 cr (+161% year on year), EBITDA ₹43.7 cr (+118% year on year), PAT ₹43.8 cr (+119% year on year), EBITDA margin 13.9% (−274 bps). Score 99 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin fell 274 bps year on year. Tax rate 9%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +54.0% in 28 days (Nifty 500: +0.3%).
  • Q3 FY26: Revenue ₹184 cr (+46% year on year), EBITDA ₹34.8 cr (+2% year on year), PAT ₹30.1 cr (+8% year on year), EBITDA margin 19.0% (−802 bps). Score 74 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin fell 802 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −8.5% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹138 cr (−5% year on year), EBITDA ₹30.0 cr (−17% year on year), PAT ₹26.0 cr (−19% year on year), EBITDA margin 21.7% (−292 bps). Score 37 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 292 bps year on year. Share price after the results: −5.2% in 28 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹137 cr (−4% year on year), EBITDA ₹25.0 cr (−29% year on year), PAT ₹25.0 cr (−14% year on year), EBITDA margin 18.3% (−640 bps). Score 25 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 640 bps year on year. Other income 29% of PBT. Share price after the results: +5.4% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹120 cr (−22% year on year), EBITDA ₹20.0 cr (−49% year on year), PAT ₹20.0 cr (−33% year on year), EBITDA margin 16.7% (−882 bps). Score 1 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 882 bps year on year. Other income 31% of PBT. Revenue fell 5% from last quarter. Share price after the results: +2.6% in 30 days (Nifty 500: +0.8%).
  • Q3 FY25: Revenue ₹126 cr (−9% year on year), EBITDA ₹34.0 cr (−15% year on year), PAT ₹28.0 cr (−15% year on year), EBITDA margin 27.0% (−200 bps). Score 15 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 200 bps year on year. Revenue fell 14% from last quarter.
  • Q2 FY25: Revenue ₹146 cr (+1% year on year), EBITDA ₹36.0 cr (−3% year on year), PAT ₹32.0 cr (0% year on year), EBITDA margin 24.7% (−86 bps). Score 29 of 100, Below trend. EBITDA margin fell 86 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Fineotex Chemical Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.